our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

Chr del(11q)

News alerts, weekly reports and conference planners

The Evaluation of Neurotrophic Receptor Tyrosine Kinase (NTRK) Alterations in Neuroblastomas. (PubMed, Front Biosci (Schol Ed))

Owing to the presence of neural tissue, NTRKs are highly positive in IHC, making these genes unsuitable as biomarkers for assessing NTRK inhibitor sensitivity and resistance, which are tissue-agnostic drugs. The observed low fusion rate is consistent with the literature, and the significance of the numerous point mutations identified as agnostic markers warrants further investigation. NTRK expression, fusion, and point mutations were not associated with clinical parameters or survival.

7 days ago

Journal

NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • NTRK (Neurotrophic receptor tyrosine kinase)

Chr del(11q) • MYCN amplification • NTRK positive • NTRK fusion

Vitrakvi (larotrectinib) • Rozlytrek (entrectinib)

22d

GFH009X2101: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML (clinicaltrials.gov)

P1/2, N=160, Recruiting, Sellas Life Sciences Group | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026

22 days ago

Trial completion date • Trial primary completion date

PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • DDX41 (DEAD-Box Helicase 41) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)

TP53 mutation • KRAS mutation • FLT3-ITD mutation • Chr del(17p) • IDH1 mutation • IDH2 mutation • FLT3 mutation • TP53 wild-type • NPM1 mutation • KRAS wild-type • Chr del(11q) • ASXL1 mutation • SF3B1 mutation • EZH2 mutation • NRAS wild-type • SRSF2 mutation • IDH wild-type

Venclexta (venetoclax) • azacitidine • tambiciclib (SLS009)

27d

Short and complex-Telomeres and genomes in CLL. (PubMed, Br J Haematol)

Br J Haematol 2026 (Online ahead of print). doi: 10.1111/bjh.70317.

27 days ago

Journal

IGH (Immunoglobulin Heavy Locus)

Chr del(11q) • IGH mutation

27d

High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights. (PubMed, Leukemia)

HGC may reflect a convergence of high-risk features rather than represent an independent biomarker. The interplay of telomere attrition, IGHV status and DNA methylation subtype necessitates further validation in targeted therapy cohorts to enhance risk assessment in prognostic models.

27 days ago

Journal

TP53 (Tumor protein P53) • NOTCH1 (Notch 1) • BIRC3 (Baculoviral IAP repeat containing 3)

TP53 wild-type • Chr del(11q)

MOONSHOT: CLL11 - A study to evaluate the efficacy of Epcoritamab consolidation in high genomic risk and Measurable Residual Disease (MRD)-positive Chronic Lymphocytic Leukaemia (CLL) patients after first-line venetoclax and obinutuzumab (ACTRN12625000387426)

P2, N=38, Recruiting, Australasian Leukaemia and Lymphoma Group (ALLG) | Not yet recruiting --> Recruiting

1 month ago

Enrollment open • Trial initiation date • Minimal residual disease

TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)

TP53 mutation • Chr del(11q)

clonoSEQ

Venclexta (venetoclax) • Gazyva (obinutuzumab) • Epkinly (epcoritamab-bysp)

2ms

Real-world disease characteristics and frontline treatments used in chronic lymphocytic leukaemia in Bulgaria: An observational cohort study (DESCRIBE). (PubMed, J Int Med Res)

Improving the rate of testing for specific high-risk molecular and genetic markers is vital to enhancing outcomes in patients with chronic lymphocytic leukaemia. In the era of proven efficacy of targeted agents, chemoimmunotherapy should be discouraged, in line with international guidelines.

2 months ago

Observational data • Journal • Real-world evidence • IO biomarker

TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • IGH (Immunoglobulin Heavy Locus)

Chr del(11q) • IGH mutation

2ms

Optical Genome Mapping Enhances Structural Variant Detection and Refines Risk Stratification in Chronic Lymphocytic Leukemia. (PubMed, Genes (Basel))

Combining OGM and NGS analysis refined risk stratification beyond standard FISH panels and supports more precise, individualized management strategies in CLL. Prospective studies are warranted to evaluate the clinical utility of OGM-guided genomic profiling in contemporary treatment paradigms.

2 months ago

Journal • IO biomarker

TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1) • IGH (Immunoglobulin Heavy Locus) • BIRC3 (Baculoviral IAP repeat containing 3) • BCL3 (BCL3 Transcription Coactivator) • MIR16 (MicroRNA 16) • MIR15A (MicroRNA 15a) • MIR16-1 (MicroRNA 16-1)

Chr del(11q) • IGH mutation • RB1 deletion

3ms

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group. (PubMed, EClinicalMedicine)

We compared an MRD-guided, fixed-duration ibrutinib-venetoclax (IV) regimen to fludarabine-cyclophosphamide-rituximab (FCR) in this population. A patient profile suitable for an MRD-guided, fixed-duration IV regimen requires consideration of potential toxicities. Abbvie and Janssen France.

3 months ago

P2 data • Journal

TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)

Chr del(11q)

Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • cyclophosphamide • fludarabine IV

3ms

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)

P2, N=42, Active, not recruiting, Jennifer Woyach | Trial completion date: Dec 2025 --> Dec 2026

3 months ago

Trial completion date

TP53 (Tumor protein P53)

Chr del(11q)

Imbruvica (ibrutinib)

3ms

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL (clinicaltrials.gov)

P2, N=22, Recruiting, Zulfa Omer | Not yet recruiting --> Recruiting

3 months ago

Enrollment open

MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • SF3B1 (Splicing Factor 3b Subunit 1) • CD79B (CD79b Molecule) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • BIRC3 (Baculoviral IAP repeat containing 3) • CD5 (CD5 Molecule) • POT1 (Protection of telomeres 1) • H1-4 (H1.4 Linker Histone, Cluster Member) • NFKBIE (NFKB Inhibitor Epsilon) • ZMYM3 (Zinc Finger MYM-Type Containing 3) • CHD2 (Chromodomain Helicase DNA Binding Protein 2) • FCER2 (Fc Fragment Of IgE Receptor II)

Chr del(11q)

clonoSEQ

Gazyva (obinutuzumab) • Epkinly (epcoritamab-bysp)

3ms

ESR-23-22182: Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL (clinicaltrials.gov)

P2, N=62, Recruiting, Zulfa Omer | Not yet recruiting --> Recruiting | Initiation date: Jun 2025 --> Dec 2025

3 months ago

Enrollment open • Trial initiation date

Chr del(11q)

clonoSEQ

Venclexta (venetoclax) • Calquence (acalabrutinib)

4ms

Neuroblastoma: prevalence of genetic alterations in different histological groups (PubMed, Arkh Patol)

Two cases with chromosomal aberrations in stromal cells were also identified. Expression of MYC protein was detected in 5 cases, of which 2 showed amplification of the MYC gene.

4 months ago

Journal

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)

Chr del(11q)